FXN and prostate carcinoma: Exposing prostate cancer cells to abiraterone and MDC3100 results in downregulation of mitochondrial proteins such as FXN (frataxin), ACO2 and TOMM20, mitochondrial swelling, mitochondrial depolarization and decreased mitochondrial DNA copy number.